OmniAb, Inc.

OmniAb, Inc. (Nasdaq: OABI) is a biotechnology company specializing in antibody discovery, offering proprietary transgenic animal platforms that help pharmaceutical and biotech partners generate novel therapeutic candidates. The company became publicly traded in October 2022 through a merger with Avista Public Acquisition Corp. II, a blank-check vehicle sponsored by Avista Capital Partners that completed its IPO in 2021. Previously a division of Ligand Pharmaceuticals, OmniAb separated to operate as an independent public entity. The 10-Q filed November 10, 2022 represents one of the company's first quarterly disclosures following the de-SPAC transaction. Sign up at SpacDesk for full filings, sponsor profiles, and deal analytics on OmniAb and the broader SPAC universe.